Modality
mAb
MOA
WEE1i
Target
Cl18.2
Pathway
T-cell
RettGastric Ca
Development Pipeline
Preclinical
~May 2010
→ ~Aug 2011
Phase 1
~Nov 2011
→ ~Feb 2013
Phase 2
~May 2013
→ ~Aug 2014
Phase 3
~Nov 2014
→ ~Feb 2016
NDA/BLA
~May 2016
→ ~Aug 2017
Approved
Nov 2017
→ Oct 2031
ApprovedCurrent
NCT08748888
677 pts·Gastric Ca
2023-05→TBD·Completed
NCT04222105
2,355 pts·Rett
2021-08→2031-10·Terminated
NCT04008926
2,751 pts·Rett
2017-11→2029-01·Terminated
5,783 total pts2 indications
CompletedCurrentUpcoming
Catalysts (2)
2029-01-082.8y awayPh3 Readout· Rett
2031-10-195.6y awayPh3 Readout· Rett
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Termina…
Approved
Termina…
Approved
Complet…
Catalysts
Ph3 Readout
2029-01-08 · 2.8y away
Rett
Ph3 Readout
2031-10-19 · 5.6y away
Rett
CompletedTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08748888 | Approved | Gastric Ca | Completed | 677 | 6MWD |
| NCT04222105 | Approved | Rett | Terminated | 2355 | VA |
| NCT04008926 | Approved | Rett | Terminated | 2751 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| GMA-1468 | Genmab | NDA/BLA | PI3Kα | |
| Talatuximab | Samsung Biologics | Preclinical | CD3 |